Monday, November 25, 2013 | |
VACCINE DESIGN | |
09.00 h | lNVITED LECTURE
Emerging viruses: a veterinary view at challenges of control at the interfaces of wildlife-livestock-humans |
T. Harder, Friedrich-Loeffler-Institut, Greifswald-Insel Riems/D | |
09.30 h |
INVITED LECTURE |
R. Moormann, Wageningen University, Lelystad and Utrecht University/NL; N. Ohreshkova, J. Kortekaas, Wageningen, Lelystad/NL | |
10.00 h |
INVITED LECTURE |
G. Sutter, University of Munich/D | |
10.30 h | New approaches for designing, control and manufacturing viral vaccines |
C. Pereira, Instituto Butantan, São Paulo/BR | |
10.50 h | A platform to determine the impact of influenza virus hemagglutinin N-glycosylation on immunogenicity |
J. Hütter, MPI of Colloids and Interfaces, Potsdam/D; J.V. Rödig, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; D. Höper, Friedrich-Loeffler-Institut, Greifswald - Insel Riems/D; P.H. Seeberger, MPI of Colloids and Interfaces, Potsdam/D; U. Reichl, MPI for Dynamics of Complex Technical Systems and University of Magdeburg/D; E. Rapp, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; B. Lepenies, MPI of Colloids and Interfaces, Potsdam/D | |
11.10 h | Coffee Break |
CELL SUBSTRATES AND ENGINEERING | |
11.30 h | Single step cloning-titration method: enabling tools for virus producer cell line development and engineering |
A.F. Rodrigues, A.S. Oliveira, M.R. Guerreiro, H. Tomas, M.J.T. Carrondo, P.M. Alves, A.S. Coroadinha, IBET - Instituto de Biologia Experimental e Tecnológica, Oeiras/P | |
11.50 h | Adaptation of a vaccine virus to production in suspension cultures |
I. Jordan, V. Sandig, ProBioGen AG, Berlin/D | |
12.10 h | Human CAP cells as novel platform for production of vaccines |
G. Schiedner, CEVEC Pharmaceuticals GmbH, Cologne/D | |
12.30 h | Capturing cell's quality: how to measure the infectability of PER.C6® cells by viruses? |
S.M. Mercier, B. Diepenbroek, Crucell, Leiden/NL; R.H. Wijffels, M. Streefland, Wageningen University/NL | |
13.00 h | Lunch Break |
BIOREACTION / UPSTREAM | |
14.00 h | INVITED LECTURE
Towards large scale AAV vector production: process development, bottlenecks, and perspectives |
O.-W. Merten, Généthon, Evry Cedex/F | |
14.30 h | INVITED LECTURE Manufacturing of AAV gene-therapy products |
A. van Oorschot, uniQure, Amsterdam/NL | |
15.00 h | Viral vector production in the integrityTM iCELLis® disposable fixed-bed bioreactor from bench-scale to industrial scale |
A. Lennaertz, S. Knowles, J.C. Drugmand, J. Castillo, ATMI LifeSciences, Brussels/B | |
15.20 h | Continuous cell culture-based influenza vaccine production |
T. Frensing, S. Heldt, I. Behrendt, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; I. Jordan, ProBioGen AG, Berlin/D; Y. Genzel, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; U. Reichl, MPI for Dynamics of Complex Technical Systems and University of Magdeburg/D | |
15.20 h | Scale-down of the inactivated polio vaccine production process |
Y.E. Thomassen, A.G. van't Oever, M. Vinke, A. Spiekstra, L.A. van der Pol, W.A.M. Bakker, Institute for Translational Vaccinology, Bilthoven/NL | |
16.00 h | Coffee Break |
ONCOLYTIC VIRUSES | |
16.15 h | INVITED LECTURE Viral gene transfer vectors: regulatory aspects and innovations in surface targeting |
C.J. Buchholz, Paul-Ehrlich-Institut, Langen/D | |
16.45 h | INVITED LECTURE Oncolytic virus production and purification challenges for human clinical trials: case study measles virus |
M. Federspiel, Mayo Clinic, Rochester, MN/USA | |
17.15 h - 18.15 h | POSTER SESSION |
P.01 | From bench scale to industrial scale: using the integrityTM iCELLis® disposable fixed-bed bioreactor to scale-up production of viral entities |
J.C. Drugmand, S. Knowles, N. Vertommen, J. Castillo, F. Debras, ATMI LifeSciences, Brussels/B | |
P.02 | Improving adenovirus purification by using enhanced membrane chromatography |
P. Nestola, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; L. Villain, Sartorius Stedim Biotech, Gottingen/D; C. Peixoto, P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; J.P.B. Mota, Requimte/CQFB, FCT/UNL, Caparica/P; M.J.T. Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P | |
P.03 | Improving viral vaccine production by interfering in the viral life cycle and by identifying new producer cell lines |
D. Oosterhoff, L. van der Pol, W.A. Bakker, Intravacc, Bilthoven/NL | |
P.04 | Development of an industrial platform for the production of rAAV |
A. Pegel, J. Wegele, M. Kunz, C. Küppers, A. Schulze, A. Rößner, D. Kreß, F. Sonntag, M. Hörer, Rentschler Biotechnologie GmbH, Laupheim/D | |
P.05 | Novel tools could give stable producer cell lines their break for commercial manufacturing of recombinant AAV vectors |
V. Emmerling, Rentschler Biotechnologie GmbH, Laupheim/D and Ulm University/D; K. Holzmann, K. Lanz, Ulm University/D; J. Wegele, Rentschler Biotechnologie GmbH, Laupheim/D; S. Kochanek, Ulm University/D; M. Hörer, Rentschler Biotechnologie GmbH, Laupheim/D | |
P.06 | Human amniocyte-derived cells for production of adenovirus vectors for gene therapy |
A.C. Silva, IBET- Instituto de Biologia Experimental e Tecnológica and ITQB-UNL, Oeiras/P; D. Simão, M.F.Q. Sousa, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; C. Küppers, T. Lucas, Ulm University, Ulm/D; P.E. Cruz, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; M.J.T. Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica and ITQB-UNL, Oeiras/P; S. Kochanek, Ulm University, Ulm/D; P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica and ITQB-UNL, Oeiras/P | |
P.07 | Chikungunya virus-like particle vaccine produced in insect cells |
S.W. Metz, J. Gardner, C. Geertsema, TT. Le, L. Goh, J.M. Vlak, A. Suhrbier, G.P. Pijlman, Wageningen University/NL | |
19:00 h |
Social Event |
Tuesday, November 26, 2013 | |
PURIFICATION / DOWNSTREAM / PROCESS CONTROL | |
09.00 h | Emerging new tools for improving downstream processing for viral vaccine and viral vectors |
P. Nestola, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; L. Villain, Sartorius Stedim Biotech, Gottingen/D; C. Peixoto, P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; J.P.B Mota, Requimte/CQFB, Departamento de Química, FCT/UNL, Caparica/P; M.J.T Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P | |
09.20 h | Can membrane chromatography streamline influenza virus purification? |
A. Cvetkovic, R. Gantier, Pall Corporation, Westborough, MA/USA; A. Onraedt, Pall International, Fribourg/CH | |
09.40 h | Purification of Enterovirus 71 like particles for vaccine production by the use of different membrane adsorbers |
M. Meininger, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; R. Djurup, Rebidu, Gentofte/DK; L. Villain, Sartorius-Stedim Biotech GmbH, Göttingen/D; J. Cardosa, Sentinext Therapeutics Sdn Bhd, Penang/MAL; U. Reichl, M. Wolff, MPI for Dynamics of Complex Technical Systems, Magdeburg/D | |
10.00 h | Ultrafiltration membranes in downstream processing for vaccine production |
T. Schleuss, H.-H. Hörl, U. Grummert, Sartorius Stedim Biotech GmbH, Göttingen/D; C. Peixoto, D. Martins, IBET, Oeiras/P | |
10.20 h | High-throughput process development for the purification of virus-like particles |
C. Ladd Effio, L. Wenger, S.A. Oelmeier, J. Hubbuch, Karlsruhe Institute of Technology (KIT)/D | |
10.40 h | Coffee Break |
11.00 h | Introduction of PAT to improve the efficiency and robustness of vaccine development and manufacturing |
A. Strancar, BIA Separations, Ajdovscina/SLO | |
11.20 h | Best practices in nucleic acid removal from vaccine processes |
F. Appel, Merck Millipore, Darmstadt/D | |
11:40 h |
Scale-up study: single use bioprocessing for influenza virus |
J. Royce, GE Healthcare Life Sciences, Uppsala/S | |
12.00 h | Purification of cell culture-derived influenza virus via continuous size exclusion chromatography |
T. Kröber, L.M. Fischer, M.W. Wolff, U. Reichl, MPI for Dynamics of Complex Technical Systems, Magdeburg/D | |
12:20 h - 13:00 h |
Wrap-up discussion |